Skip to main content

Efficacy and safety of YinQiSanHuang-antiviral decoction in chronic hepatitis B: study protocol for a randomized, placebo-controlled, double-blinded trial



Chronic hepatitis B (CHB) is a global public health problem. Antiviral therapy is the primary treatment. Studies have shown that a combined therapy of traditional Chinese medicine (TCM) and conventional antiviral drugs has better efficacy than conventional antiviral for treatment of CHB. YinQiSanHuang-antiviral decoction (YQSH) is a TCM compound preparation that has shown an effect on anti-hepatitis B virus and on slowing progression of hepatitis B-related liver diseases. To evaluate the efficacy and safety of YQSH combined with entecavir and its preventive effect on hepatitis B cirrhosis, we designed this randomized, double-blind and placebo-controlled trial. The objective is that the combination of YinQiSanHuang-antiviral decoction with entecavir will reduce the annual incidence of liver fibrosis/cirrhosis to 1%.


This is a multicenter, randomized, placebo-controlled, double-blinded trial involving five hospitals. A total of 802 patients are randomly allocated to two groups: the YQSH group (n = 401) or the placebo group (n = 401). The YQSH group receives YQSH with entecavir; the placebo group receives granules of placebo with entecavir. Patients receive treatment for 52 weeks and then are followed up for 52 ± 2 weeks. The primary outcome measure is the annual incidence of cirrhosis. The secondary outcome measures are hepatitis B virus DNA negative rate, hepatitis B surface antigen negative rate, hepatitis B e antigen seroconversion rate, liver function (alanine aminotransferase, aspartate aminotransferase , gamma-glutamyl transferase , alkaline phosphatase , serum albumin, and total bilirubin), spleen thickness, evaluation scores of patients’ clinical symptoms, and safety assessment. Outcomes will be assessed at baseline and after treatment.


Combination therapy could become a trend for treatment of CHB, and this trial expects to provide credible clinical evidence for the future combination of TCM and conventional antiviral drugs for the treatment of CHB.

Trial registration

Chinese Clinical Trial Registry: ChiCTR1900021521. Registered on 25 February 2019.

Peer Review reports


Chronic hepatitis B (CHB) is a chronic viral infection caused by hepatitis B virus (HBV) and characterized by the persistence of hepatitis B surface antigen (HBsAg) for at least 6 months (with or without concurrent hepatitis B e antigen [HBeAg]). As a global health problem, more than 257 million people worldwide suffer from chronic HBV infection [1, 2]. In 2015, an estimated 887,000 deaths resulted from hepatitis B, mostly from cirrhosis and hepatocellular carcinoma (HCC, i.e., primary liver cancer) [3]; of these CHB is responsible for 30% of all deaths from cirrhosis and 40% of those from HCC [4,5,6]. China’s prevalence is one of the highest, with about 20 million CHB cases, accounting for 21.5% of the 93 million cases of HBV infection. Without timely testing and treatment, most CHB will develop into cirrhosis, HCC, or finally lead to death [7, 8]. It is estimated that in China there are 20–30 million people with CHB, 1 million with liver cirrhosis, and 0.3 million with HCC caused by hepatitis B [9]. Deaths due to HBV-related liver diseases in China (0.308 million deaths per year) account for more than 30% of the global mortality from HBV (0.887 million deaths per year) [10]. Antiviral therapy is the primary link to slow the conversion of CHB into cirrhosis and can effectively restore liver function and improve survival rate in patients with CHB [11, 12]. Currently, the US Food and Drug Administration (FDA) has approved two types of anti-HBV drugs: interferon (IFN) and nucleos(t)ide analogs (NAs, e.g., entecavir, lamivudine, telbivudine, adefovir, and tenofovir). Although NAs are well tolerated and exhibit an early and potent antiviral effect, the selection of resistant mutants and nephrotoxicity during long-term therapy limit their use [13, 14].

Chinese herbal medicine (CHM) is one of the most popular complementary and alternative therapies for CHB, and numerous studies have reported its anti-HBV effect. CHMs have two major characteristics: (1) they are flexible and adaptable in various kinds of herbal medicines, with complex compositions, which means they do not easily cause drug resistance; (2) they are taken from the natural environment, using rich, easily obtainable sources. CHMs are generally well tolerated for long-term treatment, which provides a good therapeutic effect in the prevention and treatment of CHB. A cohort study showed that the use of CHM is associated with significantly reversed cirrhosis and reduced HCC risk in patients with CHB [15]. Many studies have identified active ingredients in single herbs or in herbal formulas that have therapeutic effects on CHB, with associated anti-HBV, antifibrosis, liver protection, antitumor, antibacterial, antioxidant, anti-acute liver injury, and anti-HCC mechanisms [16,17,18,19,20,21]. An ideal anti-HBV drug should have good safety, good drug resistance, long-lasting effects, and no withdrawal rebound, and be able to stimulate host immune responses and effectively inhibit virus replication or even eliminate the virus [22, 23]. Studies have identified that CHM not only has antiviral effects, but it also can enhance the body’s immunity to improve its antiviral ability. For example, an extract of Le-Cao-Shi, which is a kind of TCM herb, can restrain the expression of duck hepatitis B model surface antigen (DHBsAg), hepatitis B e antigen (DHBeAg), and HBV DNA (DHBV DNA), correspondingly, in a HepG2.2.15 cellular model, and could also significantly inhibit the secretions of HBsAg and HBeAg [24]. Results from another study demonstrated that cordycepin, which is extracted from TCM, could work as an adjuvant to the hepatitis B vaccine, and this type of new vaccine simultaneously improves the humoral and cellular immunity of BALB/c mice without side effects [25]. YinQiSanHuang-antiviral decoction (YQSH) is a CHM formula that has been used for more than 30 years for CHB treatment. It has shown effects on anti-HBV DNA and increasing the level of alanine aminotransferase (ALT) in a small-scale clinical study [26]. Research results suggested that YQSH not only enhances the antiviral effect of entecavir, but also has a significant preventive effect on CHB-related cirrhosis. Thus, we designed this study and have set the objective as “the combination of YQSH with entecavir will reduce the annual incidence of liver fibrosis/cirrhosis to 1%” to test the effectiveness of this combination.


Study setting

A total of 802 patients will be recruited from five centers: the main responsible unit, Xixi Hospital of Hangzhou, will recruit 162 cases, Beijing ShunYi Traditional Chinese Medicine Hospital will recruit 160 cases, the Sixth People’s Hospital of Shenyang will recruit 160 cases, Beijing DiTan Hospital Capital Medical University will recruit 160 cases, Chengdu University of Chinese Medicine Affiliated Hospital will recruit 160 cases. Figure 1 shows the flowchart of the trial.

Fig. 1

Flowchart of the randomized, placebo-controlled, double-blinded trial of YQSH for CHB. CHB chronic hepatitis B, YQSH YinQiSanHuang-antiviral decoction, HBV hepatitis B virus, HBsAg hepatitis B surface antigen, HBeAg hepatitis B e antigen, ALT alanine aminotransferase, AST aspartate aminotransferase, GGT gamma-glutamyl transferase, ALP alkaline phosphatase, ALB serum albumin, TBIL total bilirubin

Eligibility criteria

Inclusion criteria

The inclusion criteria are as follows: (1) patients who have a history of hepatitis B infection or HBsAg positive for more than 6 months, and their current HBsAg and/or HBV DNA levels are still positive; (2) patients who meet the criteria for antiviral indications in the “Asian-Pacific consensus statement on the management of CHB: a 2008 update” [27]; patients taking entecavir dispersible tablets may also be included. (This study will enroll patients who have taken entecavir previously; conversely, patients who have taken immune stimulatory drugs or other antiviral drugs within 3 months will not be enrolled.); (3) patients between 18 to 65 years old; (4) patients showing syndromes of liver stagnation and spleen deficiency and dampness in TCM. For the TCM diagnostic criteria, we refer to “National Standards for TCM Clinical Diagnosis and Treatment in the People’s Republic of China” [28] and the “Medical Consensus of diagnosis and treatment of cirrhosis with integrated TCM and Western medicine” [29], published by the Digestive System Diseases Committee, Society of Integrated Traditional Chinese and Western Medicine.

Exclusion criteria

The exclusion criteria are as follows: (1) patients with cirrhosis; (2) patients with liver cancer; (3) patients in acute and chronic hepatitis with non-HBV infection, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosis cholangitis, inherited metabolic liver disease, drug or toxic hepatitis, or alcoholic liver disease; (4) pregnant or lactating women or women planning to become pregnant during the study period; (5) patients who are allergic to the test drugs; (6) patients who have mental disorders and cannot cooperate with the study, or patients with epilepsy in unstable status; (7) patients with severe systemic disease related to the heart, brain, lung, kidney, or hematopoiesis; (8) patients with alcoholism or other unsuitable conditions for enrollment. Patients who are already using TCM will not be enrolled unless they have stopped using TCM for more than 3 months.



All patients will have a screening test during the screening period in clinic if they meet the inclusion criteria. The screening evaluation includes the patient’s general status, disease-related symptoms and signs, and corresponding laboratory tests, including the following: urine pregnancy test (women of childbearing age), HBV DNA, liver function, FibroScan, liver B-mode ultrasound or magnetic resonance imaging (MRI)/computed tomography (CT), and other examinations. The test group (YQSH group) will receive YQSH formula granules 5 g (first brewed with 150–200 ml water) twice a day, combined with entecavir 0.5 mg once a day. The control group (placebo group) will receive YQSH placebo formula granules 5 g (first brewed with 150–200 ml water) twice a day, combined with entecavir 0.5 mg once a day. The entecavir was produced by ChiaTai TianQing Pharmaceuticals in Jiangsu, China (production batch number H20100019). The main components of YQSH, totaling 14 kinds of herbs, are shown in Table 1. The test drugs are made into Chinese medicine formula granules. Before taking YQSH, the mixed formula granules are boiled with 150–200 ml water for 3–5 min. The YQSH placebo is made of excipients, thinners, coloring agents, flavoring agents, and fried malt, and is similar to YQSH in shape, color, smell, and taste.

Table 1 Main components of YinQiSanHuang-antiviral decoction


If a patient shows abnormal liver function (such as ALT > 2*ULN) during the trial, this should prompt temporary or permanent cessation of treatment, and the investigator can add hepatoprotective drugs such as silibinin and/or other drugs according to the patient’s condition. At the same time, the researchers will record and follow up the situation of the patient closely. If the patient’s ALT returns to normal after liver protection treatment, with normal values for direct bilirubin and international normalized ratio (INR) at the same time, then he/she may have a chance to continue the trial; otherwise, the patient will stop the trial permanently for safety reasons. If the following conditions occur, subjects should discontinue the trial: (1) poor compliance, irregularly taking medicine, failure to revisit or revisit on time; (2) some combined diseases or complications, or deterioration during the trial; (3) subject self-withdrawal; (4) combining trial drug with other drugs, or not taking test drugs according to research regulations; (5) lost contact; (6) cannot provide complete information.

We also list the following specific stopping criteria. (1) Serious safety problems occur during the test; then the test should be stopped in a timely manner. (2) The drug is found to have no clinical value during the trial; then the trial should be stopped to avoid delaying the effective treatment of subjects. (3) It is found during the trial that there is a major error in the clinical trial protocol and it is difficult to evaluate the effect of the drug; or there is a well-designed protocol with important deviations in the implementation, and it is difficult to continue to evaluate the efficacy and safety of the drug. (4) The sponsor requests to stop the trial (for funding reasons, management reasons, etc.). (5) The State Food and Drug Administration of China orders the trial to be stopped for some reason. (6) The test is suspended due to force majeure reasons.


The study will be regularly monitored by a Clinical Research Associate (CRA) in accordance with the corresponding standard operating procedure. The CRA will help ensure that the research center adheres to the research protocol, arranges the supply of research drugs, and ensures that the drugs are kept under appropriate conditions in accordance with instructions. At the beginning of the trial, the researcher would emphasize the importance of compliance to the subjects, and require the subjects to bring back the drug packages (regardless of the remaining drugs) when they visit the research center. At the same time, we will establish an online platform to make immediate contact with the patients, and contact them at least twice a month to learn the patients’ situations and remind them to actively return to the clinic. For those patients who participated effectively during the treatment but could not complete the entire course, and those lost to follow-up, these data will be included in the efficacy statistics and should be analyzed intentionally.

Concomitant care

Other antiviral medicines, such as tenofovir or lamivudine, must not be taken during the trial. If non-antiviral medicines are combined, they will be recorded in the case report form (CRF). If the subjects need other treatment or concomitant care, they should contact the doctor in advance.


Primary outcome

The primary outcome is the annual incidence of cirrhosis (the examination methods include instantaneous liver elastic hardness test, abdominal B-mode ultrasound test, or abdominal MRI/CT imaging).

The primary outcome is evaluated before the treatment, at 52 weeks of treatment, and at the 52 ± 2 weeks follow-up visit.

Secondary outcomes

The secondary outcomes include HBV DNA negative rate, HBsAg negative rate, HBeAg seroconversion rate, liver function (ALT, aspartate aminotransferase [AST], gamma-glutamyl transferase [GGT], alkaline phosphatase [ALP], serum albumin [ALB], and total bilirubin [TBIL]), spleen thickness, and the evaluation scores of patients’ clinical symptoms.

These indicators are observed before the treatment, at 26 weeks of treatment, at 52 weeks of treatment, at the 26 ± 2 weeks follow-up period, and at the 52 ± 2 weeks follow-up period.

Safety outcomes

The safety outcomes include adverse events (AEs), laboratory tests (liver function, kidney function, routine blood tests, routine urine tests, etc.), electrocardiography (ECG), basic vital signs, and physical examination.

The basic vital signs are body temperature, blood pressure, respiration, and heart rate; laboratory tests include renal function tests, blood urea nitrogen (BUN), creatinine (Cr), and routine blood, stool, and urine tests. These biological indicators are monitored starting from the group allocation of the patients until the end of follow-up (Fig. 2).

Fig. 2

Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) schedule of enrollment, interventions, and assessments

Participant timeline

The treatment period is 52 weeks, and the follow-up assessment period will last for 52 ± 2 weeks. We include two figures to show the participant timeline more clearly. (See Figs. 1 and 2.)

Sample size

The aim of this study is to reduce the annual incidence of cirrhosis from 2% ~ 10% [30] to 1% in patients with CHB. Therefore, according to the sample size estimation formula for comparison of two sample rates, the incidence of target events is less than 0.2 (or 0.3) or greater than 0.8 (or 0.7), shown as follows:

$$ \mathrm{n}=\frac{{\left({u}_{\alpha }+{u}_{\beta}\right)}^2}{2{\left({\mathit{\sin}}^{\hbox{-} 1}\sqrt{p_e}{\hbox{-} \mathit{\sin}}^{\hbox{-} 1}\sqrt{p_c}\right)}^2} $$

Here pe and pc represent the incidence rates of the test group (YQSH group) and placebo group (control group), respectively. The positive event rate (pc) in the control group is 5%, while the target event rate (pe) in the test group is set to 1%. Since the values of pe and pc are small, the degree is measured in radians, α = 0.05, and β = 0.10. In this study, a two-sided test was chosen, u0.05 = 1.96, u0.10 = 1.282, pe = 0.05, pc = 0.01. The calculated sample size of each group is approximately 334 cases. Therefore, allowing for 20% attrition, the total number of patients required for this trial is 334*(1 + 20%)*2 = 802 cases, with 401 in each group.


Outpatients in clinics are the main recruitment targets. Posters and online publicity containing a brief introduction to the trial and the contact information of the researchers will also be used for recruitment. Before enrollment, each patient is provided with a complete and comprehensive description of the test procedure, its purpose, potential AEs, and expected benefits. Subjects are also informed that they may withdraw from the trial. If a patient agrees to participate in the trial, he/she will sign two informed consent forms, one kept by the patient and the other kept by the researcher. Subjects with involuntary or incomplete autonomy can also enter the trial after the consent of the ethics committee, and the informed consent form will be signed by their guardian.


Sequence generation and implementation

A central randomization system (CRS) is applied to ensure a completely randomized design. The randomized system mainly includes the following modules: subject screening, randomization, emergency unblinding, drug formulation, drug supply management, and other functional modules. The central randomization principle is as follows: The researcher uses the screening module to enter some basic information for the subject (such as date of birth, gender) and obtain the subject’s unique identification number (SIN). Firstly, the researcher confirms that the patient meets the inclusion criteria, logs into the CRS, inputs the general information for the subject, generates the random number, and fills in the eCRF. Secondly, drug distributors apply for the drug number from the CRS according to the random number. Finally, the drug senders verify the code on the drug package with the number in the system, and then the drugs are given to the patients.

Concealment mechanism

In this study, the CRS is used to centrally control the allocation of the entire randomization scheme. The “central randomization” method is used to conceal the allocation: When researchers determine that the subjects are qualified, the researchers log into the CRS, enter some basic information for the subjects, and obtain the subjects’ SIN. Then, the CRS will assign the subjects’ random numbers and drug numbers according to a designed blind table. In order to make the blind method effective and reduce drug loss, the random numbers are separated from the drug numbers in this system. Although the random number and the drug number are different, their corresponding treatment plans are consistent within the system.

Blinding and emergency unblinding

This is a double-blind trial. The blinding method is set up and implemented by the Medical Statistics Center of Tianjin University of Traditional Chinese Medicine. Neither the study researchers nor the subjects know the medication grouping. In the course of the trial, a scientific and strict management implementation system and feasible operation methods are used. All the subjects are put under a standardized observation with their clinical symptoms carefully recorded. Adverse reactions are carefully observed, and emergency unblinding is required for serious adverse reactions.

A regular supervision, inspection, and return system is used to ensure the implementation of the double-blinding method.

Unblinding will be performed at the end of the trial to perform a statistical analysis of all the data. The outcome assessment will be blinded. After all the research data have been entered and locked, the third party participants who saved the blinding codes and the researchers will jointly unblind and submit the database to the statistical analyst. When the entire statistical analysis is completed, statistical analysis and clinical trial summary reports will be written by the researchers.

Data collection plan and data management

The investigator will prepare original documents for each subject who was randomized into the study, and the information will be recorded in the CRF. All research results (personal data, test documents, etc.) that appear in the original medical records will be completely confidential within the scope allowed by law. Subject names will not appear in the CRF; only the name initials and the random number will be shown. The content should be comprehensive and accurate so as to record all examination results and other relevant data. The research center shall keep these documents properly for 5 years after the end of the research. The researcher will authorize the relevant regulatory agency to directly access all research-related documents.

There are principles for handling loss to follow-up: (1) if the loss is due to adverse reactions, the data will be recorded in the adverse reaction statistics; (2) if the loss is due to ineffectiveness, the data will be included in the efficacy statistics; (3) for those patients who were effective during the treatment but could not complete the entire course, and those lost to follow-up, these data will be included in the efficacy statistics and should be analyzed intentionally.



For the statistical analysis comparing the primary outcome incidence between the two groups, we will use the χ2 test and set P < 0.05 (95% confidence interval) as statistically significant. For the secondary outcomes, the measurement data are expressed as mean ± standard deviation, the count data are expressed as frequency and percentage (f, %), and the frequency or percentage of the efficacy evaluation index is converted into frequency and percentage (f, %). For comparison of the mean between the two groups, the homogeneity test is performed first. If the variances are equal, the t test is used. If the variances are unequal, the non-parametric t test is used. The measurement data of each group before and after treatment are compared using the paired t and/or t test. The comparison of grid table count data will be performed using the χ2 test, and the comparison of rank data will use the rank sum test. P < 0.05 will be used as the statistical difference. The data analysis will be performed using SPSS 19.0 statistical software.

The baseline is defined as the last observation data before the first medication, which includes demographic characteristics and clinical baseline data: age, sex, vital signs (height, weight, temperature, heart rate, blood pressure, breathing), clinical symptom scores, HBV DNA, liver stiffness (FibroScan/Fibrotouch), entecavir treatment history, and CHB-related diseases.

Additional analyses

There are currently no plans to do subgroup analyses or sensitivity analyses.

Analysis population and missing data

We will use three methods for statistical analysis of the data:

  • Full analysis set (FAS). According to the intention-to-treat (ITT) principle, all randomized subjects’ data will enter the FAS. For subjects who withdraw from the study early for various reasons, the missing data will be imputed using the method of last observation carried forward (LOCF).

  • Per protocol set (PPS). The study’s PPS will consist of the indicator data for those who enter the study and complete treatment and follow-up, whose medication compliance is 80–120%, who took no combined medication that affected the effectiveness evaluation during the study period, and who have complete evaluation index data and no major test protocol violations.

  • Safety set (SS). The SS includes those subjects who received at least one treatment after randomization.


Formal committee and confidentiality

A data monitoring committee (DMC) will monitor the trial in accordance with the corresponding standard operating procedure, and is independent from the sponsor. The DMC will be allowed to evaluate the quality and integrity of the study. Before the start of a clinical trial, uniform training should be conducted for all the participants, including training in Good Clinical Practice (GCP), research protocols, the electronic data capture (EDC) system, central stochastic systems, and the use of scales. The DMC will assess the capabilities of the research centers and collect information about institutional facilities and technical equipment. During the period of study, the DMC is responsible for verifying the clinical research records with the original records and for resolving any problems that arise during the trial. The DMC will monitor whether written consent and dated informed consent forms have been obtained from all subjects. The DMC will also monitor that the research center adheres to the research protocol, arranges the supply of research drugs, and ensures that the drugs are kept under appropriate conditions in accordance with instructions. Each center should submit the main indicators to the clinical endpoint committee to be evaluated by uniform standards. The principal investigator and authorized researcher should review, electronically sign, and date the eCRF.

Interim analysis

The DMC has access to the interim results and makes the final decision with the sponsor and researcher on whether to terminate the trial.


Any adverse medical events that occur during treatment and follow-up, regardless of whether or not there is a causal relationship with the test medicines, should be considered as an adverse event (AE) and recorded in the specified AE table of the case report form (CRF). When filling out the AE report forms, it is necessary to record in detail the occurrence, time, severity, duration, measures taken, and outcomes of the AE. If serious AEs occur during the trial, emergency treatments should be taken immediately and the event reported to the lead researcher of the trial, the ethics committees, and the China State Food and Drug Administration Safety Supervision Department within 24 h. All AEs should be tracked until the adverse symptoms disappear or the researchers confirm that further follow-up is no longer needed.

If the subject has an injury that is directly related to this study during the course of treatment, and it is confirmed by medical identification, the research team will pay the subject’s medical expenses. For serious AEs caused by drug-related injuries, the research team will give the subject certain compensation in accordance with relevant national laws and regulations, and the compensation costs will be borne by Guang’anmen Hospital.


Beginning with enrollment, each research center will receive auditing visits every 3 months. After the data are recorded, a professional medical review will be conducted to compare the data entered in the CRF with the original data, in order to ensure the quality of the data, the clinical logic, and general medical terms for the description. The researcher will properly keep the data to protect the rights and privacy of subjects, the documents of the clinical trial shall be preserved and managed in accordance with the requirements of the GCP, and the database will be maintained by an EDC system. The auditing procedures are performed independent of the investigators.


Hepatitis B is a hidden killer. In the course of viral infection for decades, the virus carrier (patient) may show only mild symptoms, which are difficult to detected, but the infection may ultimately develop into liver cancer [31]. Currently, direct-acting antiviral agents (DAAs) including NAs and IFN can control HBV, but they cannot eliminate it completely. Therefore, pre-treatment is the best way to prevent the deterioration of CHB and cirrhosis. In the theory of TCM, there is a viewpoint of “preventive treatment of disease”, which means precautions should be taken in advance, when disease has not occurred or has just occurred, to guard against further disease development or deterioration. In China, CHM has been used for more than 2000 years and has played an important role in the prevention and treatment of disease. A TCM decoction is generally composed of various Chinese herbs in a certain proportion, and is characterized by a multi-target effect. YQSH is a TCM decoction based on the theory of preventive treatment of disease, and in early small-scale clinical observation it has suggested a potential effect on delaying the development of CHB-related cirrhosis.

At present, long-term HBV DNA inhibition or HBsAg negative status is considered to be the best surrogate endpoint for antiviral therapy in patients with CHB or cirrhosis associated with HBV [23, 32,33,34]. Studies have reported that combined therapy is superior to conventional antiviral therapies [35,36,37], in that it can not only enhance antiviral ability, but it can also reduce the accompanying symptoms, improve the quality of life, and prolong the life of patients [38, 39]. Thus, combination therapy could become a trend in CHB treatment. Looking back on the clinical research on combination therapy in CHB in recent years, there have been mostly single-center, single-field, and small-sample studies, which makes their conclusions less credible. Therefore, this trial protocol was designed into a multicenter, randomized, double-blind, placebo-controlled clinical trial, with follow-up as long as 52 ± 2 weeks, to verify the clinical efficacy and safety of the combination therapy of YQSH + entecavir, with the expectation that it will provide credible clinical evidence for the future combination of TCM and Western medicines for the treatment of CHB.

There are also some limitations to the study. Due to restrictions in research project funds and trial periods, the follow-up period could not be longer, and thus additional randomized controlled trials with long-term follow-ups are warranted. For combination therapy, there are still some problems to be clarified, such as how the drugs are combined, when is the best time for combination therapy, when to stop the drug, whether therapy can be repeated after stopping the drug, and how to cope with recurrence after drug withdrawal. It is assumed that more combination therapies will be explored in the future based on different mechanisms.

Trial status

The protocol version number is 1, and it was finalized in October 2018. Recruitment began on 21 October 2019. The approximate date when recruitment will be completed is December 2021. If we should amend the protocol, we will communicate with the investigators, ethics committee, trial registries, and other relevant parties.



Serum albumin


Alkaline phosphatase


Alanine aminotransferase


Aspartate aminotransferase


Blood urea nitrogen


Chronic hepatitis B


Chinese herbal medicine


Case report form


Central randomization system


Direct-acting antiviral agent




Food and Drug Administration


Good Clinical Practice


Gamma-glutamyl transferase


Hepatitis B virus


Hepatocellular carcinoma




Nucleos(t)ide analog


Total bilirubin


Traditional Chinese medicine


YinQiSanHuang-antiviral decoction


  1. 1.

    Revill PA, Penicaud C, Brechot C, et al. Meeting the challenge of eliminating chronic hepatitis B infection. Genes (Basel). 2019;10(4):260.

    CAS  Article  Google Scholar 

  2. 2.

    Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–55.

    Article  Google Scholar 

  3. 3.

    Liu J, Liang WN, Jing WZ, et al. Countdown to 2030: eliminating hepatitis B disease, China. Bull World Health Organ. 2019;97:230–8.

    Article  Google Scholar 

  4. 4.

    Vittal A, Ghany MG. WHO guidelines for prevention, care and treatment of individuals infected with HBV: a US perspective. Clin Liver Dis. 2019;23:417–32.

    Article  Google Scholar 

  5. 5.

    Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388:1081–8.

    Article  Google Scholar 

  6. 6.

    Dandri M, Locarnini S. New insight in the pathobiology of hepatitis B virus infection. Gut. 2012;2:16–7.

    Google Scholar 

  7. 7.

    Won LS, Hyun KJ, Lim LH, et al. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis[J]. Gut. 2019;0:1–8.

  8. 8.

    Bhattacharya D, Thio CL. Review of hepatitis B therapeutics. Clin Infect Dis. 2010;51:1201–8.

    CAS  Article  Google Scholar 

  9. 9.

    Shan S, Jia J. Advances and challenge in prevention and treatment of hepatitis B in China. Zhongguo Bingdubing Zazhi. 2017;01:5–8.

    Google Scholar 

  10. 10.

    Subic M, Zoulim F. How to improve access to therapy in hepatitis B patients. Liver Int. 2018;38(Suppl 1):115–21.

    Article  Google Scholar 

  11. 11.

    Yuen M F, Gane E J, Kim D J, et al. Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection. Gastroenterology. 2019;156:1392–403.

    Article  Google Scholar 

  12. 12.

    Calvaruso V, Craxì A. Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible? Liver Int. 2014;34:85–90.

    CAS  Article  Google Scholar 

  13. 13.

    Sun DJ, Zhu LJ, Yao DH, et al. Recent progress in potential anti-hepatitis B virus agents: structural and pharmacological perspectives. Eur J Med Chem. 2018;147:205–17.

    CAS  Article  Google Scholar 

  14. 14.

    Lee SH, Cheon GJ, Kim HS, et al. Tenofovir disoproxil fumarate monotherapy is superior to entecavir-adefovir combination therapy in patients with suboptimal response to lamivudine-adefovir therapy for nucleoside-resistant HBV: a 96-week prospective multicenter trial. Antivir Ther. 2018;23:219–27.

    Article  Google Scholar 

  15. 15.

    Tsai TY, Livneh H, Hung TH, et al. Associations between prescribed Chinese herbal medicine and risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide population-based cohort study. BMJ Open. 2017;7:e014571.

    Article  Google Scholar 

  16. 16.

    Zhao Y, Geng CA, Ma YB, et al. UFLC/MS-IT-TOF guided isolation of anti-HBV active chlorogenic acid analogues from Artemisia capillaris as a traditional Chinese herb for the treatment of hepatitis. J Ethnopharmacol. 2014;156:147–54.

    CAS  Article  Google Scholar 

  17. 17.

    Han JM, Kim HG, Choi MK, et al. Artemisia capillaris extract protects against bile duct ligation-induced liver fibrosis in rats. Exp Toxicol Pathol. 2013;65:837–44.

    CAS  Article  Google Scholar 

  18. 18.

    Zhao TT, Tang HL, Xie L, et al. Scutellaria baicalensis Georgi. (Lamiaceae): a review of its traditional uses, botany, phytochemistry, pharmacology and toxicology. J Pharm Pharmacol. 2019;71:1353–69.

    CAS  Article  Google Scholar 

  19. 19.

    Park HS, Park KI, Hong GE, et al. Korean Scutellaria baicalensis Georgi methanol extracts inhibits metastasis via the Forkhead Box M1 activity in hepatocellular carcinoma cells. J Ethnopharmacol. 2014;155:847–51.

    Article  Google Scholar 

  20. 20.

    Hsu YL, Kuo PL, Tzeng TF, et al. Huang-lian-jie-du-tang, a traditional Chinese medicine prescription, induces cell-cycle arrest and apoptosis in human liver cancer cells in vitro and in vivo. J Gastroenterol Hepatol. 2008;23:e290–9.

    Article  Google Scholar 

  21. 21.

    Ohta Y, Sasaki E, Nishida K, et al. Preventive effect of oren-gedoku-to (huanglian-jie-du-tang) extract on progression of carbon tetrachloride-induced acute liver injury in rats. Am J Chin Med. 1997;25:57–68.

    CAS  Article  Google Scholar 

  22. 22.

    European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–98.

    Article  Google Scholar 

  23. 23.

    Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261–83.

    Article  Google Scholar 

  24. 24.

    Zhao Q, Ren X, Chen M, et al. Effects of traditional Chinese medicine formula Le-Cao-Shi on hepatitis B: in vivo and in vitro studies. J Ethnopharmacol. 2019;244:112132.

    CAS  Article  Google Scholar 

  25. 25.

    Wang JB, Liu R, Liu BX, et al. Systems pharmacology-based strategy to screen new adjuvant for hepatitis B vaccine from Traditional Chinese Medicine Ophiocordyceps sinensis. Sci Rep. 2017;7:44788.

    CAS  Article  Google Scholar 

  26. 26.

    Wang DP. Clinical study of Yinzhi Sanhuang Jiedu Decoction combined with entecavir in the treatment of chronic hepatitis B. Beijing: Beijing University of Chinese Medicine; 2018. p. 63–4.

  27. 27.

    Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263–83.

    Article  Google Scholar 

  28. 28.

    State Bureau of Technical Supervision. National standards for TCM clinical diagnosis and treatment in the People’s Republic of China: symptoms section, vol. 4. Beijing: China Standard Press; 1997. p. 55.

    Google Scholar 

  29. 29.

    Chinese Society of Integrated Traditional and Western Medicine, Digestive System Diseases Committee. Consensus on diagnosis and treatment of cirrhosis with integrated traditional Chinese and Western medicine. Chin J Integr Traditional Western Med Digestion. 2011;19:277–9.

    Google Scholar 

  30. 30.

    Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B:special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335–52.

    Article  Google Scholar 

  31. 31.

    Tu T, Sandra B, Bartenschlager R. Chronic viral hepatitis and its association with liver cancer. Biol Chem. 2017;398:817–37.

    CAS  Article  Google Scholar 

  32. 32.

    Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531–61.

    Article  Google Scholar 

  33. 33.

    Testoni B, Levrero M, Zoulim F. Challenges to a cure for HBV infection. Semin Liver Dis. 2017;37:231–42.

    Article  Google Scholar 

  34. 34.

    Lok AS, Zoulim F, Dusheiko G, et al. Hepatitis B cure: from discovery to regulatory approval. J Hepatol. 2017;67:847–61.

    Article  Google Scholar 

  35. 35.

    He M, Wu Y, Wang MM, et al. Meta-analysis of the clinical value of oxymatrine on sustained virological response in chronic hepatitis B. Ann Hepatol. 2016;15:482–91.

    CAS  PubMed  Google Scholar 

  36. 36.

    Zhang L, Schuppan D. Traditional Chinese Medicine (TCM) for fibrotic liver disease: hope and hype. J Hepatol. 2014;61:166–8.

    Article  Google Scholar 

  37. 37.

    Kang H, Zhao Y, Li C, et al. Integrating clinical indexes into four-diagnostic information contributes to the Traditional Chinese Medicine (TCM) syndrome diagnosis of chronic hepatitis B. Sci Rep. 2015;5:9395.

    Article  Google Scholar 

  38. 38.

    Chen JX, Xu QX, Wang JH, et al. A case of recurrent hepatocellular carcinoma acquiring complete remission of target lesion with treatment with Traditional Chinese Medicine. Integr Cancer Ther. 2017;16:597–604.

    Article  Google Scholar 

  39. 39.

    Xiong X, Yang X, Liu Y, et al. Chinese herbal formulas for treating hypertension in traditional Chinese medicine: perspective of modern science. Hypertension Res. 2013;36:570–9.

    Article  Google Scholar 

Download references


We would like to thank Professor Zhou Bing for polishing the manuscript.


This project is sponsored by the National Key R&D Program of China (No. 2018YFC1705700).

Author information




WLL conceptualized the idea and revised it critically for intellectual content, and provided professional advice. QJW wrote the first draft of the manuscript. All authors read and approved the final manuscript. JML, TTZ, WHZ, QZ, JCW, QNW, RXZ, XZ, SL, STC, LX, JC, GHL and ZMC were involved in the conception and design, statistical advice and final approval of the manuscript, and the authors will have ultimate authority over these activities.

Corresponding author

Correspondence to Wen-Liang Lv.

Ethics declarations

Ethics approval and consent to participate

The protocol has been approved by the Medical Ethics Committee of Hangzhou Xixi Hospital, China (for central ethical approval), and the other centers in the trial will not begin recruiting until local ethical approval has been obtained. All study participants will sign two informed consent forms, one kept by the patients and the other kept by the researcher. The results of this study will be published in a peer-reviewed journal.

Consent for publication

According to the terms of the informed consent, unless the subject’s consent is obtained, all the subject’s personal information is confidential and will not be disclosed to the public. When it is necessary, the drug supervision and administration department, ethics committee, or project funding department may consult the subject’s data. Without permission, they will not use the subject’s information for other purposes or disclose it to other groups.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wu, Q., Lv, W., Li, J. et al. Efficacy and safety of YinQiSanHuang-antiviral decoction in chronic hepatitis B: study protocol for a randomized, placebo-controlled, double-blinded trial. Trials 21, 482 (2020).

Download citation


  • Chronic hepatitis B
  • Cirrhosis
  • Traditional Chinese medicine
  • Clinical trial
  • Efficacy